<bill session="110" type="h" number="2823" updated="2009-01-08T22:43:40-05:00">
	<status><introduced date="1182398400" datetime="2007-06-21"/></status>

	<introduced date="1182398400" datetime="2007-06-21"/>
	<titles>
		<title type="short" as="introduced">Fair Balance Prescription Drug Advertisement Act of 2007</title>
		<title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to deny any deduction for direct-to-consumer advertisements of prescription drugs that fail to provide certain information or to present information in a balanced manner, to amend the Federal Food, Drug, and Cosmetic Act to require reports regarding such advertisements, and to amend such Code to deny any deduction for direct-to-consumer advertisements of qualified prescription drugs for a two-year period.</title>
	</titles>
	<sponsor id="400387"/>
	<cosponsors>

	</cosponsors>
	<actions>
		<action date="1182398400" datetime="2007-06-21"><text>Sponsor introductory remarks on measure. (CR E1375)</text></action>
		<action date="1182398400" datetime="2007-06-21"><text>Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text></action>
		<action date="1182398400" datetime="2007-06-21"><text>Referred to House Ways and Means</text></action>
		<action date="1182398400" datetime="2007-06-21"><text>Referred to House Energy and Commerce</text></action>
		<action date="1182398400" datetime="2007-06-21"><committee name="House Energy and Commerce"/><text>Referred to the Subcommittee on Health.</text></action>
	</actions>
	<committees>

	</committees>
	<relatedbills>

	</relatedbills>
	<subjects>

	</subjects>
	<amendments>

	</amendments>
	<summary>
	6/21/2007--Introduced.<br/>Fair Balance Prescription Drug Advertisement Act of 2007 - Amends the Internal Revenue Code to disallow a tax deduction for: (1) expenses for direct-to-consumer prescription drug advertising that fails to provide adequate information on drug side effects, contraindications, or lack of effectiveness; and (2) expenses for direct-to-consumer prescription drug advertising of a new drug, a new combination of active substances, or a new delivery system for an existing drug for a two-year period after the introduction of such drug into interstate commerce.<br/>Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to report to the Secretary of the Treasury on misbranding and other violations relating to direct-to-consumer prescription drug advertising.<br/>
	</summary>
</bill>
